These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2778791)

  • 1. ACE inhibitors in hypertension: assessment of taste and smell function in clinical trials.
    Neil-Dwyer G; Marus A
    J Hum Hypertens; 1989 Jun; 3 Suppl 1():169-76. PubMed ID: 2778791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a beta-blocker on blood pressure reduction.
    Wald DS; Law M; Mills S; Bestwick JP; Morris JK; Wald NJ
    Clin Ther; 2008 Nov; 30(11):2030-9. PubMed ID: 19108791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum zinc is unaffected by effective captopril treatment of hypertension.
    O'Connor DT; Strause L; Saltman P; Parmer RJ; Cervenka J
    J Clin Hypertens; 1987 Dec; 3(4):405-8. PubMed ID: 3330985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-converting enzyme inhibitors in hypertension: a review.
    Salvetti A; Pedrinelli R; Arzilli F; Abdel-Haq B; Magagna A; Lucarini A; Graziadei L; Nuccorini A; Taddei S
    Int J Clin Pharmacol Res; 1985; 5(6):429-38. PubMed ID: 3005182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
    Wallis EJ; Ramsay LE; Hettiarachchi J
    Clin Pharmacol Ther; 1998 Oct; 64(4):439-49. PubMed ID: 9797801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The value of angiotensin-converting enzyme inhibitors in the treatment of hypertension].
    Klaus D
    Z Kardiol; 1988; 77 Suppl 3():73-88. PubMed ID: 3062960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor-1 and cardiac mass in essential hypertension: comparative effects of captopril, lisinopril and quinapril.
    Díez J; Laviades C
    J Hypertens Suppl; 1994 Jul; 12(4):S31-6. PubMed ID: 7965272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin converting enzyme inhibition in hypertension.
    Robertson JI; Tillman DM; Ball SG; Lever AF
    J Hypertens Suppl; 1987 Aug; 5(3):S19-25. PubMed ID: 3312525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical assessment of ACE inhibitors. Part 2.
    Howes LG
    Aust Fam Physician; 1995 Apr; 24(4):639, 641-3. PubMed ID: 7771972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impairment of taste and olfaction in patients with cirrhosis: the role of vitamin A.
    Garrett-Laster M; Russell RM; Jacques PF
    Hum Nutr Clin Nutr; 1984 May; 38(3):203-14. PubMed ID: 6746322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lisinopril: a nonsulfhydryl angiotensin-converting enzyme inhibitor.
    Noble TA; Murray KM
    Clin Pharm; 1988 Sep; 7(9):659-69. PubMed ID: 2853660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Captopril and other angiotensin converting enzyme inhibitors in the treatment of hypertension].
    Hradec J
    Vnitr Lek; 1995 May; 41(5):336-9. PubMed ID: 7653065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disturbances of taste and smell induced by drugs.
    Ackerman BH; Kasbekar N
    Pharmacotherapy; 1997; 17(3):482-96. PubMed ID: 9165552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reference-based pricing of prescription drugs: exploring the equivalence of angiotensin-converting-enzyme inhibitors.
    Bourgault C; Elstein E; Le Lorier J; Suissa S
    CMAJ; 1999 Aug; 161(3):255-60. PubMed ID: 10463046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibitors post-myocardial infarction.
    Young JB
    Cardiol Clin; 1995 Aug; 13(3):379-90. PubMed ID: 7585774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with converting-enzyme inhibitors in hypertension.
    Weber MA
    Am J Kidney Dis; 1987 Jul; 10(1 Suppl 1):45-51. PubMed ID: 3037889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hospital intensive monitoring of adverse reactions of ACE inhibitors].
    Mangrella M; Motola G; Russo F; Mazzeo F; Giassa T; Falcone G; Rossi F; D'Alessio O; Rossi F
    Minerva Med; 1998 Apr; 89(4):91-7. PubMed ID: 9676174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension.
    Favrat B; Burnier M; Nussberger J; Lecomte JM; Brouard R; Waeber B; Brunner HR
    J Hypertens; 1995 Jul; 13(7):797-804. PubMed ID: 7594444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.